芳香化酶抑制剂阿那曲唑治疗肥胖绝经后妇女的子宫内膜增生。
Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women.
作者信息
Agorastos Theodoros, Vaitsi Violeta, Pantazis Konstantinos, Efstathiadis Efstathios, Vavilis Dimitrios, Bontis John N
机构信息
Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration General Hospital, 93 Plastira Str., Aretsou, 55132 Thessaloniki, Greece.
出版信息
Eur J Obstet Gynecol Reprod Biol. 2005 Feb 1;118(2):239-40. doi: 10.1016/j.ejogrb.2004.07.002.
This is a preliminary study investigating the efficacy of aromatase inhibitor anastrozole in treating endometrial hyperplasia in obese postmenopausal women. We administered anastrozole for 12 months to 11 obese postmenopausal women with high operative risk, in order to treat endometrial hyperplasia (four simple, five complex and two atypical). Endometrial thickness in all cases and histology too in the two cases with atypia, revealed atrophical endometrium during treatment and additional mean follow-up of 10.2 months. The safety and tolerance profile was satisfactory. Anastrozole appears to be an interesting new modality for the treatment of endometrial hyperplasia in obese postmenopausal women.
这是一项初步研究，旨在调查芳香化酶抑制剂阿那曲唑治疗肥胖绝经后妇女子宫内膜增生的疗效。我们对11名手术风险高的肥胖绝经后妇女给予阿那曲唑治疗12个月，以治疗子宫内膜增生（4例单纯性、5例复杂性和2例不典型性）。所有病例的子宫内膜厚度以及2例不典型病例的组织学检查显示，在治疗期间及额外平均10.2个月的随访期内，子宫内膜呈萎缩状态。安全性和耐受性良好。阿那曲唑似乎是治疗肥胖绝经后妇女子宫内膜增生的一种有前景的新方法。
Zotero 插件